FDA clearance enables market access for a new device from DAXOR.
2 reports, 1 independent
Updated Jul 1
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA clearance enables market access for a new device from DAXOR.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- FDA approved combination clearances for Elanco's Experior use on June 27, 2025.
- Researchers from Northwestern University and Shirley Ryan AbilityLab surveyed adults using an FDA-registered device.
- The FDA requested additional clinical data from Unicycive Therapeutics.
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- FDA failed to update warning labels despite confirmed risks associated with a product.
Coverage
Newest first; wire copies grouped- GlobeNewswireDaxor Corporation Receives FDA Clearance for New Rapid, Lightweight, Blood Volume Analysis System Management Expects High Demand Driven by Speed, Simplicity, and Clinical Precision Oak Ridge, TN, Aug